Drug Profile
Research programme: cancer therapies - CPAARK and Co
Alternative Names: Cancer therapies research programme - CPAARK and CoLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator CPAARK and CO
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 17 Aug 2005 Preclinical trials in Cancer in USA (unspecified route)